Literature DB >> 29714629

Rescuing Decrepit Soluble Guanylate Cyclase: A Therapy for Sickle Cell Disease?

Paul T Schumacker1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29714629      PMCID： PMC5946336          DOI： 10.1165/rcmb.2018-0003ED

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN： 1044-1549            Impact factor:   6.914


× No keyword cloud information.
  10 in total

1.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Authors:  M Aslan; T M Ryan; B Adler; T M Townes; D A Parks; J A Thompson; A Tousson; M T Gladwin; R P Patel; M M Tarpey; I Batinic-Haberle; C R White; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Targeting Pulmonary Endothelial Hemoglobin α Improves Nitric Oxide Signaling and Reverses Pulmonary Artery Endothelial Dysfunction.

Authors:  Roger A Alvarez; Megan P Miller; Scott A Hahn; Joseph C Galley; Eileen Bauer; Timothy Bachman; Jian Hu; John Sembrat; Dmitry Goncharov; Ana L Mora; Mauricio Rojas; Elena Goncharova; Adam C Straub
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

3.  Pulmonary hypertension in sickle cell disease.

Authors:  L L Sutton; O Castro; D J Cross; J E Spencer; J F Lewis
Journal:  Am J Cardiol       Date:  1994-09-15       Impact factor: 2.778

4.  Spontaneous oxygen radical generation by sickle erythrocytes.

Authors:  R P Hebbel; J W Eaton; M Balasingam; M H Steinberg
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

5.  Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease.

Authors:  Elizabeth A Manci; Cheryl A Hillery; Carol A Bodian; Zheng G Zhang; Gerard A Lutty; Barry S Coller
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

6.  Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Authors:  Roberto F Machado; Robyn J Barst; Nancy A Yovetich; Kathryn L Hassell; Gregory J Kato; Victor R Gordeuk; J Simon R Gibbs; Jane A Little; Dean E Schraufnagel; Lakshmanan Krishnamurti; Reda E Girgis; Claudia R Morris; Erika B Rosenzweig; David B Badesch; Sophie Lanzkron; Onyinye Onyekwere; Oswaldo L Castro; Vandana Sachdev; Myron A Waclawiw; Rob Woolson; Jonathan C Goldsmith; Mark T Gladwin
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

7.  Mortality in sickle cell disease. Life expectancy and risk factors for early death.

Authors:  O S Platt; D J Brambilla; W F Rosse; P F Milner; O Castro; M H Steinberg; P P Klug
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

8.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

9.  Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.

Authors:  Karin P Potoka; Katherine C Wood; Jeffrey J Baust; Marta Bueno; Scott A Hahn; Rebecca R Vanderpool; Tim Bachman; Grace M Mallampalli; David O Osei-Hwedieh; Valerie Schrott; Bin Sun; Grant C Bullock; Eva-Maria Becker-Pelster; Matthias Wittwer; Jan Stampfuss; Ilka Mathar; Johannes-Peter Stasch; Hubert Truebel; Peter Sandner; Ana L Mora; Adam C Straub; Mark T Gladwin
Journal:  Am J Respir Cell Mol Biol       Date:  2018-05       Impact factor: 6.914

Review 10.  Sickle cell disease vasculopathy: a state of nitric oxide resistance.

Authors:  Katherine C Wood; Lewis L Hsu; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2008-01-26       Impact factor: 7.376
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.